Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Oct 22, 2010

Premium

Thermo Fisher Scientific announced this week the formation of a scientific advisory board intended to formalize its interaction with leading research centers around the world.

The newly formed board includes Thermo Fisher board member and Massachusetts Institute of Technology biology professor Tyler Jacks; Ronald Davis of Stanford University's department of biochemistry; Steven Gygi of Harvard Medical School's department of cell biology; William Hahn of Dana-Farber Cancer Institute's department of medical oncology; and David Hillyard of the University of Utah's department of pathology.


Pierre Meulien was appointed this week president and CEO of Genome Canada.

Meulien will be stepping down from his role as chief scientific officer of Genome BC to take the new position. Previously he worked as senior vice president of R&D and director of research at Aventis Pasteur.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.